Solid-Phase Peptide Synthesis: How Research Peptides Are Made

Synthesis begins with resin — polymer beads that swell in solvent — carrying a linker, a cleavable chemical handle. The first amino acid attaches to the linker by its carboxyl end, which fixes the direction of the whole process: the chain grows from C-terminus to N-terminus, one residue at a time, the reverse of how ribosomes build proteins.

Everything that follows happens on the bead. The peptide spends its entire synthesis covalently tethered, and only at the very end is it cut free.

Amino acids are double-ended by nature — an amine at one end, a carboxylic acid at the other, and often a reactive side chain in between. Mix two unprotected amino acids with a coupling agent and they join every way possible: head-to-tail, tail-to-head, chains of random length, branches off side chains.

SPPS imposes order with protecting groups — removable chemical caps that make only one bond possible at a time:

• The incoming amino acid's α-amine is capped (in the dominant modern strategy, with the Fmoc group), so it cannot couple to itself.
• Its side chain is capped with a group chosen to survive the whole synthesis (tert-butyl-type groups for acids and alcohols, trityl for others, and so on).
• Its carboxyl end is activated by a coupling reagent — converted into a form the resin-bound chain's free amine will attack.

The result: exactly one bond can form — the intended peptide bond between the activated carboxyl and the one free amine on the growing chain.

Each residue is added by the same repeated loop:

• Deprotect. A base (piperidine, for Fmoc chemistry) strips the α-amine cap from the last residue added, exposing one free amine on the resin.
• Couple. The next amino acid — side-chain-protected, carboxyl-activated, supplied in excess — is introduced and forms the new peptide bond.
• Wash. Solvent rinses carry away excess reagents and by-products; the growing chain stays on the bead.
• Repeat, for as many residues as the sequence demands.

A 5-residue peptide is a handful of cycles; a 44-residue analogue is 44 passes through the same loop (Behrendt R, et al. J Pept Sci. 2016;22(1):4–27).

When the sequence is complete, a cleavage cocktail — concentrated trifluoroacetic acid (TFA) with scavenger additives — performs two jobs at once: it cuts the linker, releasing the peptide from the resin, and it strips all the side-chain protecting groups in one global deprotection. The scavengers exist to trap the reactive fragments those departing groups become, before they can attack the freshly exposed side chains.

This step is also the answer to a question that surfaces on every Certificate of Analysis discussion: why peptides carry trifluoroacetate counterions. The peptide emerges from cleavage bathed in TFA; its basic sites pair with trifluoroacetate ions, and those counterions travel with it through purification and into the final vial — present in the mass, largely invisible to UV detection, and one of the standard reasons purity and content are different numbers.

The most important thing SPPS explains about the research-peptide market is why purity is hard, and why it gets harder with length.

No coupling is perfect. Suppose each cycle runs at 99% efficiency — an excellent figure. The fraction of chains that are complete and correct after n cycles is 0.99ⁿ:

Every chain that misses a coupling becomes a deletion sequence — the intended peptide minus one residue — chemically almost identical to the target, differing by one residue's mass. These are the characteristic impurities of SPPS: hard to separate precisely because they are so similar, and the reason the diagnostic mass offsets discussed in the mass spectrometry article matter. (Synthesis practice mitigates the problem with capping steps that terminate failed chains, converting hard-to-remove deletions into easier-to-remove truncations — but the arithmetic of compounding yield is unforgiving either way.)

Two market realities fall directly out of that table. Long peptides cost more — not linearly, because crude yield collapses with length and purification must recover the correct fraction from an increasingly crowded mixture. And a purity claim means more the longer the peptide is — 99% purity on a 44-mer represents dramatically more purification work than the same figure on a tripeptide.

The material cleaved off the resin is crude peptide — target plus deletions, truncations, and protecting-group remnants. The path to a research vial runs through:

• Preparative reverse-phase HPLC — the same separation chemistry described in the HPLC article, scaled up from analysis to production: the crude mixture is separated and only the target fraction is collected.
• Analytical verification — purity by analytical HPLC, identity by mass spectrometry, on the purified material.
• [Lyophilization](/research/lyophilization/) — the purified solution is freeze-dried into the stable cake or powder that ships.

That pipeline — synthesize, purify, verify, dry — is the full life story of every lyophilized research peptide, and each of its verification steps is what a lot's Certificate of Analysis exists to document. Certificates of Analysis are published on product pages as testing is completed — review the report before you order.